Pharmaceutical

EC approves Celltrion’s Omlyclo for allergic conditions

The EC has approved Celltrion’s Omlyclo, an omalizumab biosimilar for reference product Xolair to treat allergic conditions.

May 25, 2024 - 04:00
EC approves Celltrion’s Omlyclo for allergic conditions
The EC has approved Celltrion’s Omlyclo, an omalizumab biosimilar for reference product Xolair to treat allergic conditions.
Read the original article

Tags:

Previous Article

Cystic fibrosis: global clinical trials landscape and treatments

Next Article

Biocon and Handok link to commercialise Liraglutide in South Korea

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

PHIN-214 by PharmaIN for Portal Hypertension: Likelihood of Approval

PHIN-214 by PharmaIN for Portal Hypertension: Likelihoo...

Nov 4, 2023

Viatris gets grant for nasal spray method for treating ...

Apr 25, 2024

STAT+: Liver disease researchers are hoping AI can improve their trial design

STAT+: Liver disease researchers are hoping AI can impr...

Apr 7, 2023